Results 1 to 10 of about 2,062 (114)
Infection as an Important Factor in Medication-Related Osteonecrosis of the Jaw (MRONJ)
Medicina (Lithuania), 2021 Medication-related osteonecrosis of the jaw (MRONJ) has become a well-known side effect of antiresorptive, and antiangiogenic drugs commonly used in cancer management.
Sven Otto +2 more
exaly +3 more sources
Antioxidants, 2021 Medication-related osteonecrosis of the jaw (MRONJ) is one of the most interesting diseases in the field of maxillofacial surgery. In addition to bisphosphonates, the use of antiresorptive and antiangiogenic agents is known to be the leading cause ...
Sung-Woon On +2 more
exaly +3 more sources
Bone scan index rise prior to osteonecrosis of the jaw with bone‐modifying agents in prostate cancer [PDF]
BJUI CompassObjective This study aimed to evaluate the maximum bone scan index in the jaw (BSIJmax) before the development of clinical medication‐related osteonecrosis of the jaw (MRONJ) in patients with prostate cancer.
Masaru Tani +22 more
doaj +2 more sources
DiagnosticsMedication-related osteonecrosis of the jaw (MRONJ) is a debilitating condition associated with antiresorptive and antiangiogenic medications that are frequently used in treating osteoporosis and cancers.
Wei-Fa Yang, Yiu Yan Leung
exaly +3 more sources
Clinical and Radiological Evaluation of Oral and Maxillofacial Status in Patients Undergoing Antiresorptive Therapy and Its Relationship with MRONJ [PDF]
BiomedicinesBackground/Objectives: Patients undergoing antiresorptive therapy were evaluated, focusing on clinical and radiological features and their relationship with medication-related osteonecrosis of the jaw (MRONJ).
Marcela Wiltgen Jeffman +5 more
doaj +2 more sources
Early detection of medication-related osteonecrosis of the jaw (MRONJ) in patients with metastatic breast cancer using FDG-PET/CT scansResearch in context [PDF]
EClinicalMedicineSummary: Background: Patients with osseous metastatic breast cancer receive bone-modifying agents (BMAs) as part of their standard care. Medication-related osteonecrosis of the jaw (MRONJ) is one of the most important toxicities of this class of drugs ...
Miriam Emmelheinz +14 more
doaj +2 more sources
Frontiers in Bioengineering and Biotechnology, 2022 Despite medication-related osteonecrosis of the jaw (MRONJ) being first reported in 2003, the optimal treatment and prevention modalities for MRONJ are not clear.
Nobuyuki Kaibuchi +5 more
doaj +1 more source
Scientific Reports, 2022 Denosumab has been suggested as a first-line therapy for osteoporotic patients. However, a standardized protocol for the prevention of denosumab induced medication-related osteonecrosis of the jaw (MRONJ) has not yet been established. The purpose of this
Seoyeon Jung +5 more
doaj +1 more source
Establishment and assessment of rodent models of medication-related osteonecrosis of the jaw (MRONJ)
International Journal of Oral Science, 2022 Medication-related osteonecrosis of the jaw (MRONJ) is primarily associated with administering antiresorptive or antiangiogenic drugs. Despite significant research on MRONJ, its pathogenesis and effective treatments are still not fully understood. Animal
Ran Yan +5 more
doaj +1 more source
Journal of Dental Sciences, 2021 Background/purpose: Because the anatomy and the nature of the bone tissue between the mandible and maxilla are largely different, more site-specific studies are required to improve the healing rate on medication-related osteonecrosis of the jaw (MRONJ ...
Kohei Okuyama +8 more
doaj +1 more source